Christian M Hedrich

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/3015599/publications.pdf

Version: 2024-02-01

154 papers	6,637 citations	43973 48 h-index	76769 74 g-index
180 all docs	180 docs citations	180 times ranked	7336 citing authors

#	Article	IF	Citations
1	Panel sequencing links rare, likely damaging gene variants with distinct clinical phenotypes and outcomes in juvenile-onset SLE. Rheumatology, 2023, 62, SI210-SI225.	0.9	9
2	Classification of systemic lupus erythematosus in children and adults. Clinical Immunology, 2022, 234, 108898.	1.4	13
3	Systemic lupus erythematosus â€“ Are children miniature adults?. Clinical Immunology, 2022, 234, 108907.	1.4	14
4	Longitudinal analysis of urinary proteins in lupus nephritis â€“ A pilot study. Clinical Immunology, 2022, 236, 108948.	1.4	4
5	RIP2-deficiency induces inflammation in response to SV40 Large T induced genotoxic stress through altered ROS homeostasis. Clinical Immunology, 2022, 238, 108998.	1.4	1
6	Attainment of low disease activity and remission targets reduces the risk of severe flare and new damage in childhood lupus. Rheumatology, 2022, 61, 3378-3389.	0.9	17
7	TNF-inhibitors or bisphosphonates in chronic nonbacterial osteomyelitis? - Results of an international retrospective multicenter study. Clinical Immunology, 2022, 238, 109018.	1.4	19
8	Working Towards a Treat-to-Target Protocol in Juvenile Proliferative Lupus Nephritis â€“ A Survey of Pediatric Rheumatologists and Nephrologists in Germany and Austria. Frontiers in Pediatrics, 2022, 10, 851998.	0.9	4
9	Real world treatment of juvenile-onset systemic lupus erythematosus: Data from the UK JSLE cohort study. Clinical Immunology, 2022, 239, 109028.	1.4	6
10	WS12.06 Hypertonic saline triggers inflammatory responses in human macrophages. Journal of Cystic Fibrosis, 2022, 21, S24.	0.3	0
11	A panel of urinary proteins predicts active lupus nephritis and response to rituximab treatment. Rheumatology, 2021, 60, 3747-3759.	0.9	26
12	Is it time to re-think juvenile-onset Rheumatic and Musculoskeletal Diseases? â€“ First steps towards individualised treatments to meet agreed targets. Clinical Immunology, 2021, 223, 108647.	1.4	2
13	Outcome of chronic granulomatous disease â€•Conventional treatment vs stem cell transplantation. Pediatric Allergy and Immunology, 2021, 32, 576-585.	1.1	21
14	Antiphospholipid-Syndrom bei Kindern und Jugendlichen. Springer Reference Medizin, 2021, , 1-18.	0.0	0
15	Clinical and laboratory phenotypes in juvenile-onset Systemic Lupus Erythematosus across ethnicities in the UK. Lupus, 2021, 30, 597-607.	0.8	24
16	Chronic nonbacterial osteomyelitis (CNO) and chronic recurrent multifocal osteomyelitis (CRMO). Journal of Translational Autoimmunity, 2021, 4, 100095.	2.0	48
17	Biosimilars in der pÃdiatrischen Rheumatologie. Springer Reference Medizin, 2021, , 1-6.	0.0	0
18	Systemic Lupus Erythematosus in Children and Young People. Current Rheumatology Reports, 2021, 23, 20.	2.1	64

#	Article	IF	Citations
19	Is chronic non-infectious osteomyelitis with mandibular involvement a distinct disease?. Lancet Rheumatology, The, 2021, 3, e90-e92.	2.2	2
20	Limited sensitivity and specificity of the ACR/EULAR-2019 classification criteria for SLE in JSLE?â€"observations from the UK JSLE Cohort Study. Rheumatology, 2021, 60, 5271-5281.	0.9	21
21	Therapeutic approaches to pediatric COVID-19: an online survey of pediatric rheumatologists. Rheumatology International, 2021, 41, 911-920.	1.5	3
22	Diagnosis and Treatment of Angiography Positive Medium to Large Vessel Childhood Primary Angiitis of Central Nervous System (p-cPACNS): An International Survey. Frontiers in Pediatrics, 2021, 9, 654537.	0.9	11
23	The Molecular Pathophysiology of Psoriatic Arthritisâ€"The Complex Interplay Between Genetic Predisposition, Epigenetics Factors, and the Microbiome. Frontiers in Molecular Biosciences, 2021, 8, 662047.	1.6	29
24	Cyclic AMP Response Element Modulator-Î± Suppresses PD-1 Expression and Promotes Effector CD4+ T Cells in Psoriasis. Journal of Immunology, 2021, 207, 55-64.	0.4	4
25	Drug delivery systems as immunomodulators for therapy of infectious disease: Relevance to COVID-19. Advanced Drug Delivery Reviews, 2021, 178, 113848.	6.6	6
26	Juvenile Idiopathic Arthritis Associated Uveitis. Children, 2021, 8, 646.	0.6	15
27	Editorial: Focusing on T-Cells for Novel Treatments of Systemic Lupus Erythematosus. Frontiers in Immunology, 2021, 12, 744866.	2.2	2
28	Serum protein signatures differentiate paediatric autoimmune/inflammatory disorders. Clinical Immunology, 2021, 229, 108790.	1.4	4
29	Comment on: Limited sensitivity and specificity of the ACR/EULAR-2019 classification criteria for SLE in JSLE?: Reply. Rheumatology, 2021, , .	0.9	0
30	Establishing core domain sets for Chronic Nonbacterial Osteomyelitis (CNO) and Synovitis, Acne, Pustulosis, Hyperostosis, Osteitis (SAPHO): A report from the OMERACT 2020 special interest group. Seminars in Arthritis and Rheumatism, 2021, 51, 957-961.	1.6	7
31	Cardiac pathology and outcomes vary between Kawasaki disease and PIMS-TS. Clinical Immunology, 2021, 229, 108780.	1.4	14
32	1675â€...Real world treatment of juvenile systemic lupus erythematosus (JSLE): evidence from the UK JSLE cohort study. , 2021, , .		0
33	Diagnosis and Treatment of Small Vessel Childhood Primary Angiitis of the Central Nervous System (sv-cPACNS): An International Survey. Frontiers in Pediatrics, 2021, 9, 756612.	0.9	9
34	DNA Methylation Patterns in CD8+ T Cells Discern Psoriasis From Psoriatic Arthritis and Correlate With Cutaneous Disease Activity. Frontiers in Cell and Developmental Biology, 2021, 9, 746145.	1.8	11
35	Neuropsychiatric involvement in juvenile-onset systemic lupus erythematosus: Data from the UK Juvenile-onset systemic lupus erythematosus cohort study. Lupus, 2021, 30, 1955-1965.	0.8	16
36	Innately Adaptive or Truly Autoimmune: Is There Something Unique About Systemic Juvenile Idiopathic Arthritis?. Arthritis and Rheumatology, 2020, 72, 210-219.	2.9	33

#	Article	IF	Citations
37	High-dose intravenous methylprednisolone in juvenile non-infectious uveitis: A retrospective analysis. Clinical Immunology, 2020, 211, 108327.	1.4	8
38	Linking genetic variation with epigenetic profiles in SjÃ¶gren's syndrome. Clinical Immunology, 2020, 210, 108314.	1.4	10
39	SARS-CoV-2 infections in children and young people. Clinical Immunology, 2020, 220, 108588.	1.4	82
40	Presentation, Treatment Response and Short-Term Outcomes in Paediatric Multisystem Inflammatory Syndrome Temporally Associated with SARS-CoV-2 (PIMS-TS). Journal of Clinical Medicine, 2020, 9, 3293.	1.0	56
41	Vasculitis in Cystic Fibrosis. Frontiers in Pediatrics, 2020, 8, 585275.	0.9	4
42	New Insights into Adult and Paediatric Chronic Non-bacterial Osteomyelitis CNO. Current Rheumatology Reports, 2020, 22, 52.	2.1	57
43	Urine and serum S100A8/A9 and S100A12 associate with active lupus nephritis and may predict response to rituximab treatment. RMD Open, 2020, 6, e001257.	1.8	21
44	COVID-19 in children and young people. Lancet Rheumatology, The, 2020, 2, e514-e516.	2.2	35
45	Novel paediatric presentation of COVID-19 with ARDS and cytokine storm syndrome without respiratory symptoms. Lancet Rheumatology, The, 2020, 2, e376-e379.	2.2	49
46	Differential analysis of serum and urine S100 proteins in juvenile-onset systemic lupus erythematosus (jSLE). Clinical Immunology, 2020, 214, 108375.	1.4	19
47	COVID-19 â€“ Considerations for the paediatric rheumatologist. Clinical Immunology, 2020, 214, 108420.	1.4	49
48	COVID-19: Immunology and treatment options. Clinical Immunology, 2020, 215, 108448.	1.4	485
49	Clinical and laboratory characteristics in juvenile-onset systemic lupus erythematosus across age groups. Lupus, 2020, 29, 474-481.	0.8	62
50	Lupus IgG deposition causes arthritis but inhibits bone destruction through competitive occupation of FcÎ³RI and reduced RANKL signalling. Clinical and Translational Immunology, 2020, 9, e1174.	1.7	7
51	Biosimilars in pediatric rheumatology and their introduction into routine care. Clinical Immunology, 2020, 216, 108447.	1.4	6
52	Distinct interferon signatures and cytokine patterns define additional systemic autoinflammatory diseases. Journal of Clinical Investigation, 2020, 130, 1669-1682.	3.9	142
53	Orbital inflammation and colitis in pediatric IgG4-related disease: A case report and review of the literature. European Journal of Rheumatology, 2020, 7, 21-27.	1.3	4
54	Vaskulitiden. Springer Reference Medizin, 2020, , 1123-1130.	0.0	0

#	Article	IF	Citations
55	The German National Registry of Primary Immunodeficiencies (2012â€“2017). Frontiers in Immunology, 2019, 10, 1272.	2.2	71
56	CASP1 variants influence subcellular caspase-1 localization, pyroptosome formation, pro-inflammatory cell death and macrophage deformability. Clinical Immunology, 2019, 208, 108232.	1.4	9
57	cAMP Response Element Modulator Î± Induces Dual Specificity Protein Phosphatase 4 to Promote Effector T Cells in Juvenile-Onset Lupus. Journal of Immunology, 2019, 203, 2807-2816.	0.4	21
58	Juvenile-onset systemic lupus erythematosus: Update on clinical presentation, pathophysiology and treatment options. Clinical Immunology, 2019, 209, 108274.	1.4	94
59	P40â€ƒS100A8/A9 and S100A12 may be biomarkers for juvenile-onset systemic lupus erythematosus. Rheumatology, 2019, 58, .	0.9	0
60	The Role of Epigenetics in Autoimmune/Inflammatory Disease. Frontiers in Immunology, 2019, 10, 1525.	2.2	161
61	Defining consensus opinion to develop randomised controlled trials in rare diseases using Bayesian design: An example of a proposed trial of adalimumab versus pamidronate for children with CNO/CRMO. PLoS ONE, 2019, 14, e0215739.	1.1	19
62	Pharmacoepigenetics of Systemic Lupus Erythematosus. , 2019, , 597-608.		0
63	I017â€ƒThe molecular pathophysiology of CNO and consequences for patient care. Rheumatology, 2019, 58, .	0.9	0
64	Vasculitis in Juvenile-Onset Systemic Lupus Erythematosus. Frontiers in Pediatrics, 2019, 7, 149.	0.9	19
65	Interference of canakinumab with commercial IL-1Î² ELISAs. Clinical Immunology, 2019, 205, 6-7.	1.4	1
66	Outcomes following mycophenolate mofetil versus cyclophosphamide induction treatment for proliferative juvenile-onset lupus nephritis. Lupus, 2019, 28, 613-620.	0.8	33
67	Chronic Non-Bacterial Osteomyelitis. , 2019, , 563-585.		2
68	FRI0574â€…CLINICAL RESPONSE TO HIGH-DOSE INTRAVENOUS METHYLPREDNISOLONE IN CHILDHOOD AUTOIMMUNE UVEITIS: A RETROSPECTIVE ANALYSIS. , 2019, , .		0
69	SP0187â€…PATHOPHYSIOLOGY AND THERAPEUTIC CONSEQUENCES AUTO-INFLAMMATORY BONE DISORDERS. , 2019, , .		0
70	OP0193â€…CAMP RESPONSE ELEMENT MODULATOR (CREM)A INDUCES DUAL SPECIFICITY PROTEIN PHOSPHATASE (DUSP)4 THROUGH EPIGENETIC REMODELING, PROMOTING IL-17A AND REDUCING IL-2 EXPRESSION IN T CELLS. , 2019, , .		0
71	Mast cells enhance sterile inflammation in chronic nonbacterial osteomyelitis. DMM Disease Models and Mechanisms, 2019, 12, .	1.2	10
72	SNPs talk to genes using landlines: long-range chromatin interactions link genetic risk with epigenetic patterns in Takayasu arteritis. Annals of the Rheumatic Diseases, 2019, 78, 1293-1295.	0.5	1

#	Article	IF	Citations
73	The role of epigenetics in paediatric rheumatic disease. Current Opinion in Rheumatology, 2019, 31, 450-463.	2.0	7
74	Chronic Nonbacterial Osteomyelitis. , 2019, , 227-248.		0
75	Vaskulitiden bei Kindern und Jugendlichen. Springer Reference Medizin, 2019, , 1-8.	0.0	0
76	Bone Pain in Upper Leg, Hip, Lower Back. , 2019, , 583-590.		1
77	IL10 promoter haplotypes may contribute to altered cytokine expression and systemic inflammation in celiac disease. Clinical Immunology, 2018, 190, 15-21.	1.4	5
78	TCRÎ±Î² + CD3 + CD4 â^' CD8 â^' (double negative) T cells in autoimmunity. Autoimmunity Reviews, 2018, 17, 422-430.	2.5	94
79	Mechanistic aspects of epigenetic dysregulation in SLE. Clinical Immunology, 2018, 196, 3-11.	1.4	27
80	Cell-Specific Requirements for STAT Proteins and Type I IFN Receptor Signaling Discretely Regulate IL-24 and IL-10 Expression in NK Cells and Macrophages. Journal of Immunology, 2018, 200, 2154-2164.	0.4	17
81	CD14+ monocytes contribute to inflammation in chronic nonbacterial osteomyelitis (CNO) through increased NLRP3 inflammasome expression. Clinical Immunology, 2018, 196, 77-84.	1.4	33
82	An optimized whole blood assay measuring expression and activity of NLRP3, NLRC4 and AIM2 inflammasomes. Clinical Immunology, 2018, 191, 100-109.	1.4	13
83	Consensus Treatment Plans for Chronic Nonbacterial Osteomyelitis Refractory to Nonsteroidal Antiinflammatory Drugs and/or With Active Spinal Lesions. Arthritis Care and Research, 2018, 70, 1228-1237.	1.5	128
84	Autoinflammatory mutation in NLRC4 reveals a leucine-rich repeat (LRR)â€"LRR oligomerization interface. Journal of Allergy and Clinical Immunology, 2018, 142, 1956-1967.e6.	1.5	52
85	Approaches to Autoimmune Diseases Using Epigenetic Therapy. , 2018, , 387-405.		2
86	Kawasaki Disease. Frontiers in Pediatrics, 2018, 6, 198.	0.9	54
87	Practice and consensus-based strategies in diagnosing and managing systemic juvenile idiopathic arthritis in Germany. Pediatric Rheumatology, 2018, 16, 7.	0.9	72
88	Childhood Vasculitis. Frontiers in Pediatrics, 2018, 6, 421.	0.9	45
89	Treatment Response and Longterm Outcomes in Children with Chronic Nonbacterial Osteomyelitis. Journal of Rheumatology, 2017, 44, 1058-1065.	1.0	99
90	TCR + CD3 + CD4 â^' CD8 â^' effector T cells in psoriasis. Clinical Immunology, 2017, 181, 51-59.	1.4	39

#	Article	IF	Citations
91	Epigenetics in SLE. Current Rheumatology Reports, 2017, 19, 58.	2.1	79
92	Chronic Recurrent Multifocal Osteomyelitis (CRMO): Presentation, Pathogenesis, and Treatment. Current Osteoporosis Reports, 2017, 15, 542-554.	1.5	171
93	DNA methylation in systemic lupus erythematosus. Epigenomics, 2017, 9, 505-525.	1.0	86
94	Juvenile-onset systemic lupus erythematosus (jSLE) â€“ Pathophysiological concepts and treatment options. Best Practice and Research in Clinical Rheumatology, 2017, 31, 488-504.	1.4	62
95	SLE-Associated Defects Promote Altered T Cell Function. Critical Reviews in Immunology, 2017, 37, 39-58.	1.0	21
96	Neurotrophin Receptor p75NTR Regulates Immune Function of Plasmacytoid Dendritic Cells. Frontiers in Immunology, 2017, 8, 981.	2.2	14
97	Serum Interleukin-6 and CCL11/Eotaxin May Be Suitable Biomarkers for the Diagnosis of Chronic Nonbacterial Osteomyelitis. Frontiers in Pediatrics, 2017, 5, 256.	0.9	28
98	The molecular pathophysiology of chronic non-bacterial osteomyelitis (CNO)â€”a systematic review. Molecular and Cellular Pediatrics, 2017, 4, 7.	1.0	39
99	Childhood primary large vessel CNS vasculitis: single-centre experience and review of the literature. Clinical and Experimental Rheumatology, 2017, 35 Suppl 103, 213-220.	0.4	7
100	Enzymatically Inactive Procaspase 1 stabilizes the ASC Pyroptosome and Supports Pyroptosome Spreading during Cell Division. Journal of Biological Chemistry, 2016, 291, 18419-18429.	1.6	13
101	Serum biomarkers for the diagnosis and monitoring of chronic recurrent multifocal osteomyelitis (CRMO). Rheumatology International, 2016, 36, 769-779.	1.5	61
102	Chronic Nonbacterial Osteomyelitis: Pathophysiological Concepts and Current Treatment Strategies. Journal of Rheumatology, 2016, 43, 1956-1964.	1.0	84
103	Unexpectedly high incidences of chronic non-bacterial as compared to bacterial osteomyelitis in children. Rheumatology International, 2016, 36, 1737-1745.	1.5	101
104	Shaping the spectrum â€” From autoinflammation to autoimmunity. Clinical Immunology, 2016, 165, 21-28.	1.4	76
105	Acrodermatitis Chronica Atrophicans. Journal of Pediatrics, 2016, 170, 335-335.e1.	0.9	1
106	Epigenetics and the Regulation of Inflammation. , 2015, , 85-111.		1
107	Current understanding of the pathophysiology of systemic juvenile idiopathic arthritis (sJIA) and target-directed therapeutic approaches. Clinical Immunology, 2015, 159, 72-83.	1.4	60
108	Altered expression of IL-10 family cytokines in monocytes from CRMO patients result in enhanced IL-1Î² expression and release. Clinical Immunology, 2015, 161, 300-307.	1.4	88

#	Article	IF	Citations
109	Fluorescent tags influence the enzymatic activity and subcellular localization of procaspase-1. Clinical Immunology, 2015, 160, 172-179.	1.4	8
110	cAMP Responsive Element Modulator (CREM) Î± Mediates Chromatin Remodeling of CD8 during the Generation of CD3+CD4â^'CD8â^' T Cells. Journal of Biological Chemistry, 2014, 289, 2361-2370.	1.6	66
111	Stat3 promotes IL-10 expression in lupus T cells through trans- activation and chromatin remodeling. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 13457-13462.	3.3	148
112	Epigenetic regulation of cytokine expression in systemic lupus erythematosus with special focus on T cells. Autoimmunity, 2014, 47, 234-241.	1.2	59
113	CaMK4-dependent activation of AKT/mTOR and CREM-Î± underlies autoimmunity-associated Th17 imbalance. Journal of Clinical Investigation, 2014, 124, 2234-2245.	3.9	185
114	cAMP responsive element modulator: a critical regulator of cytokine production. Trends in Molecular Medicine, 2013, 19, 262-269.	3.5	77
115	Autoinflammatory bone disorders with special focus on chronic recurrent multifocal osteomyelitis (CRMO). Pediatric Rheumatology, 2013, 11, 47.	0.9	155
116	Autoinflammatory bone disorders. Clinical Immunology, 2013, 147, 185-196.	1.4	86
117	Bridging the gap between autoinflammation and autoimmunity. Clinical Immunology, 2013, 147, 151-154.	1.4	19
118	Gene-function studies in systemic lupus erythematosus. Nature Reviews Rheumatology, 2013, 9, 476-484.	3.5	99
119	Protein Phosphatase 2A Enables Expression of Interleukin 17 (IL-17) through Chromatin Remodeling. Journal of Biological Chemistry, 2013, 288, 26775-26784.	1.6	77
120	A clinical and pathomechanistic profile of chronic nonbacterial osteomyelitis/chronic recurrent multifocal osteomyelitis and challenges facing the field. Expert Review of Clinical Immunology, 2013, 9, 845-854.	1.3	49
121	cAMP-responsive Element Modulator Î± (CREMÎ±) trans-Represses the Transmembrane Glycoprotein CD8 and Contributes to the Generation of CD3+CD4â^'CD8â^' T Cells in Health and Disease. Journal of Biological Chemistry, 2013, 288, 31880-31887.	1.6	53
122	The Catalytic Subunit of Protein Phosphatase 2A (PP2Ac) Promotes DNA Hypomethylation by Suppressing the Phosphorylated Mitogen-activated Protein Kinase/Extracellular Signal-regulated Kinase (ERK) Kinase (MEK)/Phosphorylated ERK/DNMT1 Protein Pathway in T-cells from Controls and Systemic Lupus Erythematosus Patients. Journal of Biological Chemistry, 2013, 288, 21936-21944.	1.6	91
123	THU0004â€...Camp responsive element modulator (CREM) alpha contributes to decreased NOTCH-1 expression in T cells from patients with systemic lupus erythematosus (SLE). Annals of the Rheumatic Diseases, 2013, 71, 155.1-155.	0.5	0
124	Update: Cytokine Dysregulation in Chronic Nonbacterial Osteomyelitis (CNO). International Journal of Rheumatology, 2012, 2012, 1-7.	0.9	65
125	cAMP response element modulator Î± controls IL2 and IL17A expression during CD4 lineage commitment and subset distribution in lupus. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 16606-16611.	3.3	92
126	Dynamic CpG-DNA Methylation of Il10 and Il19 in CD4+ T Lymphocytes and Macrophages: Effects on Tissue-Specific Gene Expression. Klinische Padiatrie, 2012, 224, 53-60.	0.2	16

#	Article	IF	Citations
127	Increased Expression of SLAM Receptors SLAMF3 and SLAMF6 in Systemic Lupus Erythematosus T Lymphocytes Promotes Th17 Differentiation. Journal of Immunology, 2012, 188, 1206-1212.	0.4	65
128	cAMP-responsive Element Modulator Î± (CREMÎ±) Contributes to Decreased Notch-1 Expression in T Cells from Patients with Active Systemic Lupus Erythematosus (SLE). Journal of Biological Chemistry, 2012, 287, 42525-42532.	1.6	44
129	cAMP-responsive Element Modulator Î± (CREMÎ±) Suppresses IL-17F Protein Expression in T Lymphocytes from Patients with Systemic Lupus Erythematosus (SLE). Journal of Biological Chemistry, 2012, 287, 4715-4725.	1.6	61
130	Attenuated TLR4/MAPK signaling in monocytes from patients with CRMO results in impaired IL-10 expression. Clinical Immunology, 2012, 145, 69-76.	1.4	97
131	A novel isoform of the orphan receptor RORÎ³t suppresses IL-17 production in human T cells. Genes and Immunity, 2012, 13, 346-350.	2.2	19
132	CD3-T Cell Receptor Co-stimulation through SLAMF3 and SLAMF6 Receptors Enhances RORÎ³t Recruitment to the IL17A Promoter in Human T Lymphocytes. Journal of Biological Chemistry, 2012, 287, 38168-38177.	1.6	22
133	Anakinra: A safe and effective first-line treatment in systemic onset juvenile idiopathic arthritis (SoJIA). Rheumatology International, 2012, 32, 3525-3530.	1.5	41
134	â€œMutation negativeâ€•familial cold autoinflammatory syndrome (FCAS) in an 8-year-old boy: clinical course and functional studies. Rheumatology International, 2012, 32, 2629-2636.	1.5	15
135	Epigenetic patterns in systemic sclerosis and their contribution to attenuated CD70 signaling cascades. Clinical Immunology, 2012, 143, 1-3.	1.4	13
136	Biological properties and regulation of IL-10 related cytokines and their contribution to autoimmune disease and tissue injury. Clinical Immunology, 2012, 143, 116-127.	1.4	149
137	Pilot study: possible association of IL10 promoter polymorphisms with CRMO. Rheumatology International, 2012, 32, 555-556.	1.5	38
138	Presentations and Treatment of Childhood Scleroderma: Localized Scleroderma, Eosinophilic Fasciitis, Systemic Sclerosis, and Graft-Versus-Host Disease. Clinical Pediatrics, 2011, 50, 604-614.	0.4	25
139	Epigenetic mechanisms in systemic lupus erythematosus and other autoimmune diseases. Trends in Molecular Medicine, 2011, 17, 714-724.	3.5	154
140	MENINGOENCEPHALITIS CAUSED BY VARICELLA-ZOSTER VIRUS REACTIVATION IN A CHILD WITH DOMINANT PARTIAL INTERFERON-GAMMA RECEPTOR-1 DEFICIENCY. Pediatric Infectious Disease Journal, 2011, 30, 265-266.	1.1	13
141	Chronic non-bacterial osteomyelitis is associated with impaired Sp1 signaling, reduced IL10 promoter phosphorylation, and reduced myeloid IL-10 expression. Clinical Immunology, 2011, 141, 317-327.	1.4	91
142	Early onset systemic lupus erythematosus: differential diagnoses, clinical presentation, and treatment options. Clinical Rheumatology, 2011, 30, 275-283.	1.0	25
143	Chorioretinitis in a 7-Year-Old African Girl, Probably Related to JSSc Resolving to Methotrexate Therapy. Klinische Padiatrie, 2011, 223, 92-94.	0.2	0
144	cAMP-responsive Element Modulator (CREM)Î± Protein Induces Interleukin 17A Expression and Mediates Epigenetic Alterations at the Interleukin-17A Gene Locus in Patients with Systemic Lupus Erythematosus. Journal of Biological Chemistry, 2011, 286, 43437-43446.	1.6	122

#	Article	IF	Citations
145	cAMP-responsive Element Modulator (CREM)Î± Protein Signaling Mediates Epigenetic Remodeling of the Human Interleukin-2 Gene. Journal of Biological Chemistry, 2011, 286, 43429-43436.	1.6	81
146	Genetic Variation and Epigenetic Patterns in Autoimmunity. Journal of Genetic Syndromes & Gene Therapy, 2011, 02, .	0.2	10
147	Cell type-specific regulation of IL-10 expression in inflammation and disease. Immunologic Research, 2010, 47, 185-206.	1.3	180
148	Dynamic DNA methylation patterns across the mouse and human IL10 genes during CD4+ T cell activation; influence of IL-27. Molecular Immunology, 2010, 48, 73-81.	1.0	27
149	A humanIL10BAC transgene reveals tissue-specific control of IL-10 expression and alters disease outcome. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 17123-17128.	3.3	44
150	Autosomal Dominant Neurohypophyseal Diabetes Insipidus in Two Families. Hormone Research in Paediatrics, 2009, 71, 111-119.	0.8	8
151	Chilblain lupus erythematosusâ€"a review of literature. Clinical Rheumatology, 2008, 27, 949-954.	1.0	101
152	Chilblain lupus erythematosusâ€"a review of literature. Clinical Rheumatology, 2008, 27, 1341-1341.	1.0	24
153	Stat4-dependent, T-bet-independent regulation of IL-10 in NK cells. Genes and Immunity, 2008, 9, 316-327.	2.2	65
154	Good response to ILâ€1Î² blockade by anakinra in a 23â€yearâ€old CINCA/NOMID patient without mutations in theCIAS1gene. Cytokine profiles and functional studies. Scandinavian Journal of Rheumatology, 2008, 37, 385-389.	0.6	17